Taevas
South KoreaPharmaceuticals
Legal Representation
Legal Representation for Pharmaceuticals in South
Taevas Global provides qualified local legal representation for foreign pharmaceuticals manufacturers entering South Korea, ensuring full compliance with MFDS requirements so you can focus on growth rather than regulatory risk.
Market
South Korea
Industry
Pharmaceuticals
Service
Legal Representation
Regulator
Ministry of Food and Drug Safety (MFDS)
Timeline
4-8 weeks to appointment
What We Deliver
Six Pillars of South Pharmaceuticals Intelligence
Our legal representation service is built on six interconnected pillars that cover every dimension of regulatory compliance, market access, and ongoing obligations for pharmaceuticals companies in South Korea.
01
Regulatory Compliance Management
We act as your designated local representative under the Pharmaceutical Affairs Act, ensuring all MFDS submissions, notifications, and post-market obligations are handled accurately and on time. Our team monitors regulatory updates and translates compliance requirements into actionable steps for your organization.
Designated local representative appointment under Pharmaceutical Affairs Act
Ongoing MFDS submission management and tracking
Proactive monitoring of regulatory amendments affecting your product portfolio
How It Works
From Brief to Board-Ready Intelligence
Our four-step engagement model takes you from initial scoping through to a fully operational legal representation structure in South Korea, with clear milestones and transparent communication at every stage.
Step 1 · Day 1-3
Regulatory Scoping and Needs Assessment
We begin with a structured intake session to understand your product portfolio, existing regulatory status, and market entry objectives. Our team reviews your current documentation and identifies the specific MFDS obligations that apply to your product category, whether prescription drugs, biologics, or OTC medicines.
Taevas Approach
This phase produces a written regulatory scoping report that maps every applicable requirement under the Pharmaceutical Affairs Act and relevant MFDS guidelines to your specific product type. The report includes a gap analysis against your existing global dossier, a timeline projection for each regulatory milestone, and a clear cost estimate for the full engagement. You receive this document before any formal agreement is signed, ensuring complete transparency.
Market Snapshot
South Pharmaceuticals Market at a Glance
$0B
South Korea Pharmaceutical Market Size (2023)
0%
Projected Annual Market Growth Rate
0+
Licensed Foreign Pharmaceutical Manufacturers
0+
New Drug Approvals Filed Annually with MFDS
MFDS as a Stringent Regulatory Authority
South Korea's Ministry of Food and Drug Safety is recognized as one of Asia's most rigorous regulatory bodies, with review standards closely aligned to ICH guidelines and mutual recognition agreements with the United States FDA and European EMA. Foreign manufacturers must appoint a qualified local representative before submitting any drug product application, making legal representation a non-negotiable first step. Failure to maintain a registered local representative can result in immediate suspension of market authorization.
National Health Insurance Coverage as a Market Gateway
South Korea operates a single-payer National Health Insurance system administered by the Health Insurance Review and Assessment Service, and reimbursement listing is critical to commercial viability for most pharmaceutical products. The listing process involves health technology assessment, price negotiation, and ongoing cost-effectiveness reviews that require active local representation and government affairs capability. Products not listed on the reimbursement formulary face severely limited market uptake in the hospital and clinic channels.
Growing Demand for Innovative and Biologic Therapies
South Korea has seen accelerating demand for biologic medicines, biosimilars, and targeted oncology therapies, supported by government investment in biopharmaceutical manufacturing infrastructure and favorable regulatory pathways for expedited review of innovative drugs. The Korean government's Bio-Health Industry Innovation Strategy has earmarked significant funding to position South Korea as a global biologics manufacturing hub, creating commercial opportunities for foreign companies with novel pipelines. This environment rewards early market entry with strong legal and regulatory foundations.
Digital Health and Pharmaceutical Technology Integration
South Korea's advanced digital infrastructure and high adoption of electronic health records are accelerating the integration of digital therapeutics and AI-assisted drug development into the mainstream pharmaceutical market. MFDS has introduced dedicated regulatory pathways for digital therapeutics and combination products, requiring manufacturers to navigate both pharmaceutical and software device regulations simultaneously. Companies entering this space benefit significantly from a local representative with cross-functional expertise spanning pharmaceutical law and digital health regulation.
What's Included
Everything in Your Report
Every Legal Representation engagement with Taevas Global delivers a structured set of documents, filings, and ongoing services designed to keep your pharmaceutical business fully compliant and commercially active in South Korea.
Regulatory Scoping Report
A written assessment of all MFDS obligations applicable to your product portfolio, including a gap analysis against your existing global documentation and a milestone timeline for achieving market authorization.
MFDS Appointment Documentation Package
All formally executed and filed documents confirming Taevas Global as your designated local representative, including power of attorney, MFDS notification records, and certified confirmation of acceptance.
Korean CTD Dossier Adaptation
A fully adapted Korean Common Technical Document prepared from your existing global dossier, incorporating certified translations, local module requirements, and any Korea-specific data supplements required by MFDS.
Pharmacovigilance System Setup
Establishment and documentation of a Korea-compliant local pharmacovigilance system, including standard operating procedures for adverse event collection, evaluation, and expedited reporting to MFDS.
Market Authorization Filing and Tracking
End-to-end management of your drug product application submission to MFDS, including query response coordination and a live tracking dashboard showing current review status and upcoming deadlines.
Compliance Calendar and Obligation Register
A structured annual compliance calendar mapping every filing deadline, renewal date, and reporting obligation for your South Korea product portfolio, updated in real time as regulatory requirements evolve.
Regulatory Intelligence Monitoring
Ongoing monitoring of MFDS regulatory updates, new guidance documents, and legislative changes affecting the pharmaceutical sector, delivered as a monthly briefing with recommended actions for your portfolio.
Stakeholder Engagement Reports
Documented records of all interactions with MFDS, HIRA, and other government bodies on your behalf, including meeting minutes, correspondence summaries, and recommended follow-up actions.
Who This Is For
Built for These Situations
First-Time Market Entrant
Foreign Manufacturer Entering South Korea for the First Time
Your company has a product approved in your home market and is ready to pursue South Korea as a priority export destination, but you have no existing local entity, no MFDS-registered representative, and limited familiarity with Korean pharmaceutical law. The mandatory local representative requirement means you cannot file a single document with MFDS until this appointment is in place. Taevas Global provides the fastest compliant path from zero presence to active regulatory engagement.
Outcome
Achieve MFDS-registered local representation and submit your first drug product application within eight weeks of engagement.
Next Steps
After Legal Representation, Most Clients Move To
FAQ
Common Questions
Get Started
Ready to Map Your South Opportunity?
Taevas Global's legal representation specialists are ready to assess your South Korea pharmaceutical market entry requirements and deliver a clear, compliant path to MFDS registration and commercial launch. Contact us today to begin your regulatory scoping.
MFDS-compliant local representative appointment within weeks
End-to-end dossier preparation and submission management
Integrated pharmacovigilance and ongoing compliance support
Dedicated account manager with South Korea pharmaceutical expertise